Table of contents
How this target is built
A price target here is simply: Forward EPS × Assumed P/E multiple. Two inputs, both uncertain:
- Forward EPS estimate — based on recent earnings trend and management commentary on growth drivers.
- Assumed P/E multiple — anchored to the stock’s own 3-year average multiple, adjusted up or down for sector sentiment.
Scenario table
| Scenario | FY27E EPS (₹) | Assumed P/E | Implied Price (₹) | Key assumption |
|---|---|---|---|---|
| Bear case | 58 | 22x | 1,276 | Margin compression from pricing pressure in LatAm generics |
| Base case | 66 | 27x | 1,782 | Earnings grow in line with 3-year historical CAGR |
| Bull case | 74 | 32x | 2,368 | New geography approvals accelerate growth + re-rating |
What would move this target
| Factor | Effect if positive | Effect if negative |
|---|---|---|
| Regulatory approvals (new markets) | Re-rating tailwind | Delay caps upside |
| Currency (INR vs LatAm currencies) | Margin tailwind | Margin headwind |
| Sector-wide pharma sentiment | Multiple expansion | Multiple compression regardless of fundamentals |
Technical cross-check
A price target built purely on fundamentals should still be checked against chart structure before treating any near-term entry as “confirmed” — an overbought RSI/MFI reading or a stock trading far above its 20-day moving average is a reason to wait for a better entry even if the fundamental target looks attractive.
Bottom line
Read price targets as a transparent set of assumptions, not a promise. If you disagree with the growth or multiple assumption used here, the target changes — that is the exercise. Always cross-reference with your own research and, for any real capital decision, a SEBI-registered adviser.
StockRanker Research Desk
The StockRanker Research Desk publishes independent, educational market and personal-finance content for Indian readers. We are not SEBI-registered analysts or advisers.
